XML 175 R118.htm IDEA: XBRL DOCUMENT v3.25.0.1
Investments accounted for using the equity method - Summary of Principal Transactions and Balances with Related Parties (Details) - Associates and joint ventures - EUR (€)
€ in Millions
 12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Dec. 31, 2022
Disclosure of transactions between related parties [line items]      
Sales(d) [1] € 103 € 157 € 131 [2]
Royalties and other income(d) [1] 71 14 21 [2]
Accounts receivable and other receivables [3] 184 249 330 [2]
Other Assets, Related Party Transactions [4] 189 0 0 [2]
Purchases and other expenses (including research expenses)(d) [1] 600 573 472 [2]
Accounts payable and other liabilities 160 € 190 258 [2]
EUROAPI      
Disclosure of transactions between related parties [line items]      
Subordinate Hybrid Bond, Related Party Transactions € 189   € 200
[1] (d)Figures for comparative periods (2023 and 2022) have been re-presented on a consistent basis to reflect the classification of Opella as a discontinued
operation.
[2] (a)In 2022, these items include Sanofi's transactions with EUROAPI from May 10, 2022 (see Note D.1.).
[3] (b)Includes loans to joint ventures and associates.
[4] (c)In October 2024, Sanofi raised its investment in EUROAPI by €200 million in the form of a perpetual subordinated hybrid bond. The fair value of this
investment as of December 31, 2024 is €189 million.